Clinical Trials Logo

Filter by:
NCT ID: NCT04906434 Recruiting - Clinical trials for Advanced Liver Cancer

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Start date: February 26, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 study with an escalation part and an expansion part.

NCT ID: NCT04906317 Recruiting - Colonoscopy Clinical Trials

The Effectiveness of Sedation and Analgesia in Colonoscopy Treatment of Colorectal Polyps

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

This study aims to evaluate the effectiveness of sedation and analgesia in the treament of colorectal polyps by colonoscopy.

NCT ID: NCT04906083 Recruiting - Thrombocytopenia Clinical Trials

Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.

NCT ID: NCT04906031 Recruiting - Clinical trials for Acute Myeloid Leukemia

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list. The list includes 65 p53 mutations that were experimentally confirmed to be pharmacologically restored with tumor-suppressive function by antimonials.

NCT ID: NCT04905732 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Nasal High-frequency Oscillatory Ventilation (NHFOV) for Ventilated Newborn Infants With BPD

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

Invasive ventilation(IV) remains one key cornerstone to reduce neonatal mortality for preterm infants with respiratory distress syndrome(RDS) and/or acute respiratory distress syndrome(ARDS). However, it is also related to increased risks of ventilator-associated lung injury and escalation of pulmonary inflammation, and which finally result in bronchopulmonary dysplasia (BPD). Early weaning from IV in newborn infants with BPD is therefore a key procedure to reduce these risks above.

NCT ID: NCT04905602 Recruiting - Asthma Clinical Trials

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Start date: June 15, 2021
Phase: Phase 1
Study type: Interventional

This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.

NCT ID: NCT04905550 Recruiting - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease. Patients with EGFR positive-type had a 10-15% higher risk of brain metastasis than patients with EGFR wild-type. mOS in patients with EGFR positive were twice as high as those with EGFR wild-type, despite the presence of brain metastasis. Improving the control rate of intracranial lesions in patients with EGFR positive can not only improve the quality of life, but also may translate into survival benefits and improve OS. Previous studies have shown that in lung cancer patients with EGFR-sensitive mutations, craniocerebral radiotherapy prior to delayed craniocerebral radiotherapy significantly prolonged OS. The first-line treatment of the third generation of EGFR-TKI targeting drug Almonertinib for EGFR-positive NSCLC can eliminate the possible EGFR T790M mutant clones at an early stage and better control the disease progression. Moreover, Almonertinib is easy to pass through the blood-brain barrier, which can not only better control intracranial lesions, but also control, prevent or delay the occurrence of brain metastasis. This study was intended to conduct a randomized controlled study on the safety and efficacy of early craniocerebral radiotherapy combined with Almonertinib in patients with EGFR positive non-small cell lung cancer with brain metastasis. Through the above studies we hope to confirm that early craniocerebral radiotherapy combined with Almonertinib is safe and feasible for patients with EGFR positive newly diagnosed with brain metastasis, and can prolong the intracranial progression-free survival (IPFS), and even extend the progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT04905537 Recruiting - Newborn Clinical Trials

Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness

Start date: January 1, 2021
Phase:
Study type: Observational

The researchers hope to establish an overall program of early genetic screening for neonatal critical illness in China, and to develop precise intervention strategies to assist clinical diagnosis and treatment of hereditary critical illness.

NCT ID: NCT04905199 Recruiting - Tachyarrhythmia Clinical Trials

Temporary Transvenous Pacemaker Placement by Intracavitary Electrocardiogram Monitoring

Start date: March 25, 2021
Phase:
Study type: Observational

Traditional temporary pacing catheter insertion by intracavitary electrocardiogram (IC-ECG) monitoring which only monitoring tip polar, the negative one. The investigators modified the technique by monitoring both negative and positive polar which will be precisely locating catheter tip and indicating the direction of the catheter tip. Extensively used temporary pacing catheter tip has two electrodes which are about 1 cm apart. Distal electrode is negative (-) and active, proximal electrode is positive (+) and indifferent. Investigators use both distal (-) and proximal (+) electrodes which can be attached to any two of the V leads, record as V(-) and V(+). Monitoring positions of the electrodes by V(-) and V(+) could provide more information about the tip position. Comparing the QRS amplitudes between V(-) and V(+), when catheter tip enters right ventricle chamber: the case of V(-) > V(+) infers tip toward apex ventricle wall ; conversely, the case of V(-)<V(+) indicates tip directs to outflow tract. The investigators hypothesis this monitoring will help precisely placement.

NCT ID: NCT04905056 Recruiting - Progression Clinical Trials

A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules